Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Salarius Pharmaceuticals stock
Learn how to easily invest in Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 16 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Salarius Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – SLRX. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Salarius Pharmaceuticals stock price (NASDAQ: SLRX)Use our graph to track the performance of SLRX stocks over time.
Salarius Pharmaceuticals shares at a glance
|Latest market close||$2.42|
|52-week range||$1.07 - $13.46|
|50-day moving average||$1.91|
|200-day moving average||$4.29|
|Wall St. target price||$70.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.38|
Buy Salarius Pharmaceuticals stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Salarius Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Salarius Pharmaceuticals price performance over time
|1 week (2023-01-23)||-15.09%|
|1 month (2022-12-30)||58.17%|
|3 months (2022-10-28)||19.21%|
|6 months (2022-07-29)||1,173.68%|
|1 year (2022-01-28)||462.79%|
|2 years (2021-01-29)||118.02%|
|3 years (2020-01-30)||2.65|
|5 years (2018-01-30)||4.19|
Salarius Pharmaceuticals financials
|Gross profit TTM||$-6,708,304|
|Return on assets TTM||-40.33%|
|Return on equity TTM||-99.02%|
|Market capitalisation||$5.6 million|
TTM: trailing 12 months
Salarius Pharmaceuticals share dividends
We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.
Have Salarius Pharmaceuticals's shares ever split?
Salarius Pharmaceuticals's shares were split on a 1:25 basis on 16 October 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.
Salarius Pharmaceuticals share price volatility
Over the last 12 months, Salarius Pharmaceuticals's shares have ranged in value from as little as $1.07 up to $13.4575. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Salarius Pharmaceuticals's is 0.8391. This would suggest that Salarius Pharmaceuticals's shares are less volatile than average (for this exchange).
Salarius Pharmaceuticals overview
Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. .
Salarius Pharmaceuticals in the news
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
Frequently asked questionsWhat percentage of Salarius Pharmaceuticals is owned by insiders or institutions?
Currently 8.271% of Salarius Pharmaceuticals shares are held by insiders and 16.327% by institutions. How many people work for Salarius Pharmaceuticals?
Latest data suggests 16 work at Salarius Pharmaceuticals. When does the fiscal year end for Salarius Pharmaceuticals?
Salarius Pharmaceuticals's fiscal year ends in December. Where is Salarius Pharmaceuticals based?
Salarius Pharmaceuticals's address is: 2450 Holcombe Boulevard, Houston, TX, United States, 77021 What is Salarius Pharmaceuticals's ISIN number?
Salarius Pharmaceuticals's international securities identification number is: US79400X1072 What is Salarius Pharmaceuticals's CUSIP number?
Salarius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 79400X107
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert